0120 Merck KGaA bintrafusp alfa
BioCentury & Getty Images

Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

Phase III miss in NSCLC raises questions about the hypothesis that TGFβ can help overcome checkpoint resistance

Phase III miss in NSCLC raises questions about the hypothesis that TGFβ can help overcome checkpoint resistance. 

Jan 21, 2021 | 2:03 AM GMT

The Phase III miss for Merck KGaA’s

Read the full 652 word article

How to gain access

Continue reading with a
two-week free trial.